Search is Powered by Google
Arthritis / Rheumatology News

Vioxx Successor Arcoxia May Have Similar Heart Attack Risks

rate icon Featured Article
Main Category: Arthritis / Rheumatology
Also Included In: Pain / Anesthetics;  Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 13 Sep 2006 - 8:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 and a half stars

4.3 (10 votes)

Health Professional:4 stars

3.85 (13 votes)

Article Opinions: 1 posts

Arcoxia, a new experimental painkiller Merck & Co hope will become the successor of Vioxx, which was taken off the market because of its heart attack risks, may have similar risks, say scientists who looked at 23 clinical trials comparing several painkillers.

You can read about this new report in JAMA (the Journal of the American Medical Association).

In fact, the report showed that Vioxx and diclofenac carried similar cardiovascular risks (diclofenac is a much older painkiller). According to a Merck study, Arcoxia and diclofenac (Voltaren) have the same risks.

Vioxx raises cardiovascular risk by approximately 35%, diclofenac raises cardiovascular risk by about 40%. Voltaren (diclofenac) is currently sold in 62 countries.

By arguing that Arcoxia is no worse than diclofenac will not logically get it approved by the FDA if Vioxx and diclofenac carried similar risks. Arcoxia has already been turned down by the FDA (2004) because of insufficient safety data.

If you found the information above confusing, perhaps the alternative explanation below may make it clearer.

1. Vioxx was taken off the market some time ago because of heart attack and stroke risk.

2. Voltaren (diclofenac) is still sold in 62 countries and has similar risks to Vioxx.

3. Merck compares Arcoxia, a new experimental drug, to diclofenac, saying Arcoxia has similar risks. As the drug is still on the market it is saying Arcoxia is not more dangerous than a drug which is still on the market.

4. Why would the FDA approve Arcoxia if it has similar risks to diclofenac, which has similar risks to Vioxx?

"COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk"
"The Seduction of Common Sense"
David J. Graham, MD, MPH
JAMA. 2006;296:(doi:10.1001/jama.296.13.jed60058).
Click Here To Read Article Online

Written by: Christian Nordqivst
Editor Medical News Today

View drug information on Vioxx.

Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
What is Arthritis? What Causes Arthritis?
28 Mar 2009
The word arthritis comes from the Greek arthron meaning "joint" and the Latin itis meaning "inflammation". The plural of arthritis is arthritides. Arthritis affects the musculoskeletal system, specifically the joints...


Diagnosing Vision Problems in Children
Diagnosing Vision Problems in Children

Children with vision problems are often misidentified as having learning disabilities, especially since the kids themselves may not be aware there's a problem with their sight. But parents should look for warning signs of vision trouble.

more videos are available in our health videos section.